(Q34046858)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

review article

1 reference

title

Design and evaluation of antigen-specific vaccination strategies against cancer (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

author name string

R Offringa

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

S H van der Burg

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

F Ossendorp

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

C J Melief

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

publication date

1 October 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

Current Opinion in Immunology

31 October 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

volume

12

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

page(s)

576-582

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

issue

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells

31 October 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Cell-based vaccination against melanoma--background, preliminary results, and perspective

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Regression of human metastatic renal cell carcinoma after vaccination with tumor cell-dendritic cell hybrids

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Strategies for immunotherapy of cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Complete molecular remissions induced by patient-specific vaccination plus granulocyte-monocyte colony-stimulating factor against lymphoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

A recombinant vaccinia virus encoding human papillomavirus types 16 and 18, E6 and E7 proteins as immunotherapy for cervical cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Detection of T helper responses, but not of human papillomavirus-specific cytotoxic T lymphocyte responses, after peptide vaccination of patients with cervical carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Phase IIa safety and immunogenicity of a therapeutic vaccine, TA-GW, in persons with genital warts

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Autoaggression and tumor rejection: it takes more than self-specific T-cell activation.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Coupling and uncoupling of tumor immunity and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Generation of cytotoxic T-cell responses with synthetic melanoma-associated peptides in vivo: implications for tumor vaccines with melanoma-associated antigens

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Phase I study in melanoma patients of a vaccine with peptide-pulsed dendritic cells generated in vitro from CD34(+) hematopoietic progenitor cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Tumor eradication by wild-type p53-specific cytotoxic T lymphocytes.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

The use of HLA A2.1/p53 peptide tetramers to visualize the impact of self tolerance on the TCR repertoire

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Peptide-based cancer vaccines

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Genetic immunization against neu/erbB2 transgenic breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Vaccination with the extracellular domain of p185neu prevents mammary tumor development in neu transgenic mice

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Targeting HER-2/neu for active-specific immunotherapy in a mouse model of spontaneous breast cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Specific T helper cell requirement for optimal induction of cytotoxic T lymphocytes against major histocompatibility complex class II negative tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Protective anti-tumor immunity induced by vaccination with recombinant adenoviruses encoding multiple tumor-associated cytotoxic T lymphocyte epitopes in a string-of-beads fashion

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Harnessing self-reactivity in cancer immunotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Processing of some antigens by the standard proteasome but not by the immunoproteasome results in poor presentation by dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

An autologous oral DNA vaccine protects against murine melanoma

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Immune response to a differentiation antigen induced by altered antigen: a study of tumor rejection and autoimmunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

High frequencies of naive Melan-A/MART-1-specific CD8(+) T cells in a large proportion of human histocompatibility leukocyte antigen (HLA)-A2 individuals

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Monitoring CD8 T cell responses to NY-ESO-1: correlation of humoral and cellular immune responses.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Ex vivo staining of metastatic lymph nodes by class I major histocompatibility complex tetramers reveals high numbers of antigen-experienced tumor-specific cytolytic T lymphocytes

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

An expanded peripheral T cell population to a cytotoxic T lymphocyte (CTL)-defined, melanocyte-specific antigen in metastatic melanoma patients impacts on generation of peptide-specific CTLs but does not overcome tumor escape from immune surveillanc

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Two subsets of memory T lymphocytes with distinct homing potentials and effector functions

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Rapid conversion of naive to effector T cell function counteracts diminished primary human newborn T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

In situ detection of virus- and tumor-specific T-cell immunity

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Detection of antigen-specific T cells with multivalent soluble class II MHC covalent peptide complexes.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

Monoclonal antibody therapy for resected Dukes' C colorectal cancer: seven-year outcome of a multicenter randomized trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0952-7915%2800%2900145-X

7 January 2021

10.1016/S0952-7915(00)00145-X

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11007362%20AND%20SRC:MED&resulttype=core&format=json

31 October 2019

1 reference